Our Company
Targeson is a biotechnology company that develops, manufactures, and markets ultrasound contrast agent technologies for pre-clinical molecular imaging in animal models. Targeson is also developing this technology for site-specific diagnosis and therapy in humans. The company has engineered a versatile microparticle platform that may be used as both a contrast agent and, in a slightly modified form, a drug or gene delivery agent. Targeson manufactures and sells the TargestarTM line of contrast agents for ultrasound-based molecular and functional imaging in animal models of disease. Targeson’s agents can be readily targeted to the unique molecular signature of many diseases, and can be used to detect pathophysiology on the molecular level. The company’s innovative intellectual property enables the agents to bind with high efficiency to the intended molecular targets. In addition, the company is investigating therapeutic technology for simultaneous imaging and delivery, which enables the user to verify that the therapeutic compound has been delivered to the intended site. Targeson is headquartered in Charlottesville, VA.